Description

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon—showing extraordinary potential for weight loss and metabolic improvements in Phase 2 and Phase 3 clinical trials. The 10 mg formulation is commonly used during dose escalation protocols as researchers transition from lower initiation doses to higher target strengths.